Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 6/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24786861 | 0.89 | HTR7 (0.41) | NMT1HTR7HTR1AGAA | |
| SCHEMBL10093022 | 0.74 | GAA (0.41) | NMT1GAAALDH1A1 | |
| SCHEMBL24786522 | 0.73 | GAA (0.33) | GAA | |
| SCHEMBL26945695 | 0.67 | GAA (0.38) | GAAALDH1A1 | |
| SCHEMBL5718812 | 0.64 | NOS3 (0.37) | NOS3NOS1NOS2HRH4HRH3 | |
| SCHEMBL22083451 | 0.63 | GAA (0.34) | GAA | |
| SCHEMBL31582398 | 0.62 | GAA (0.37) | NMT1GAA | |
| SCHEMBL13799633 | 0.62 | ALDH1A1 (0.40) | GAAALDH1A1 | |
| SCHEMBL23400750 | 0.60 | MAPK8 (0.34) | NMT1GAAALDH1A1 | |
| SCHEMBL14981439 | 0.60 | PDE5A (0.38) | NMT1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273948-A1 | USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273948-A1 | USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS | SIGMAR1, OPRL1, OPRK1 | NMT1 2925/4885HTR7 99/4885HTR1A 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.